Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Master protocol trial for rare hepato-pancreato-biliary cancers and neuroendocrine-related rare tumor subsets
jRCTs031220099Recruiting
- Start
- Aug 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of paclitaxel, gemcitabine, oxaliplatin, folinic acid, irinotecan and 3 more in pancreatic cancer (PC), pancreatic acinar cell carcinoma (PACC), pancreatic adenocarcinoma (PDAC) and 1 more (4 cohorts). Primary endpoint: Objective response rate. Started Aug 2022; status: recruiting.
02
Drugs
paclitaxelgemcitabineoxaliplatinfolinic acidirinotecan
03
Conditions
pancreatic cancer (PC)pancreatic acinar cell carcinoma (PACC)pancreatic adenocarcinoma (PDAC)Hepatocholangiocarcinoma (HCC-CC)
Beyond the preview
Go deeper on jRCTs031220099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220099.